These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8085014)

  • 41. Future shock: drug therapy and the U.S. pharmaceutical industry.
    Ellenhorn MJ
    J Clin Pharmacol; 1975; 15(5-6):385-400. PubMed ID: 1133216
    [No Abstract]   [Full Text] [Related]  

  • 42. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970.
    Tobbell DA
    Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nurse moral distress: a proposed theory and research agenda.
    Corley MC
    Nurs Ethics; 2002 Nov; 9(6):636-50. PubMed ID: 12450000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding moral habitability: a framework to enhance the quality of the clinical environment as a workplace.
    Vanderheide R; Moss C; Lee S
    Contemp Nurse; 2013 Aug; 45(1):101-13. PubMed ID: 24099231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [PRESENT EXPERIENCES WITH THE STABILITY OF DRUGS IN THE PHARMACEUTICAL INDUSTRY].
    PALKOSKA J
    Cesk Farm; 1963 Dec; 12():520-3. PubMed ID: 14118729
    [No Abstract]   [Full Text] [Related]  

  • 46. [Health care professionals and the pharmaceutical industry].
    Duce Gracia F
    Arch Bronconeumol; 2005 Jul; 41(7):357-9. PubMed ID: 16029726
    [No Abstract]   [Full Text] [Related]  

  • 47. [Epidemiology and the pharmaceutical industry].
    Walker AM; García Rodríguez LA; Pérez Gutthann S
    Med Clin (Barc); 1992 Mar; 98(12):465-8. PubMed ID: 1573915
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmaceutical expenditure compared across countries.
    van Mosseveld C
    Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Orphan drugs from the perspective of research-based pharmaceutical and biotech companies].
    Sydow S; Throm S
    Internist (Berl); 2019 Apr; 60(4):405-410. PubMed ID: 30859276
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharma faces major challenges after a year of failures and heated battles.
    Frantz S
    Nat Rev Drug Discov; 2007 Jan; 6(1):5-7. PubMed ID: 17269157
    [No Abstract]   [Full Text] [Related]  

  • 51. Biotech products pose distribution challenges.
    Szeinbach SL; Gillenwater EL
    Am Pharm; 1994 Mar; NS34(3):19-20. PubMed ID: 8192094
    [No Abstract]   [Full Text] [Related]  

  • 52. [USE OF PLASTMASS FOR PACKAGING OF PREPARED DRUGS].
    CHUKHLEBOV KS
    Med Prom SSSR; 1964 Apr; 18():34-7. PubMed ID: 14191535
    [No Abstract]   [Full Text] [Related]  

  • 53. [Tendencies in drug research].
    Westerling R
    Sven Farm Tidskr; 1966 Apr; 70(12):293-6. PubMed ID: 5911655
    [No Abstract]   [Full Text] [Related]  

  • 54. [The pharmaceutical industry in France: the turning point of 1915].
    Bonnemain B
    Rev Hist Pharm (Paris); 2015 Dec; 63(388):399-422. PubMed ID: 26827550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

  • 56. Moral injury and moral repair in war veterans: a preliminary model and intervention strategy.
    Litz BT; Stein N; Delaney E; Lebowitz L; Nash WP; Silva C; Maguen S
    Clin Psychol Rev; 2009 Dec; 29(8):695-706. PubMed ID: 19683376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mega-mergers in the pharmaceutical industry. In whose interests?
    Po AL
    Pharmacoeconomics; 1998 Oct; 14(4):349-55. PubMed ID: 10344903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Market mortality of new products in the pharmaceutical industry.
    Norwood GJ; Smith MC
    J Am Pharm Assoc; 1971 Nov; 11(11):592-6. PubMed ID: 5133102
    [No Abstract]   [Full Text] [Related]  

  • 59. The utility of pharmacokinetics to the pharmaceutical industry.
    Nelson RL
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):565-9. PubMed ID: 977797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80. PubMed ID: 11659537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.